Gubra AS 2024 AR2

The report highlights Gubra's outstanding performance in 2024, marked by a 31% organic revenue growth in its contract research organization (CRO) business and positive Phase 1a clinical results for its anti-obesity drug candidate, GUBamy. The company advanced its transition from biotechnology to techbio, utilizing its proprietary streaMLine drug discovery platform and establishing a new TechBio lab. In sustainability, Gubra committed to the Science Based Targets initiative (SBTi) and progressed toward its goals of electric power self-sufficiency by 2025 and becoming carbon-negative and nature-positive by 2030. Additionally, the company maintained equal gender representation on its Board of Directors and other management teams.

Company: Gubra AS

Sector: Health Care

Country: Denmark

Year: 2024

Type: AR2

Pages: 118

Gubra AS 2024 Annual Report

Annual Report

The report highlights Gubra's outstanding performance in 2024, marked by a 31% organic revenue growth in its contract research organization (CRO) business and positive Phase 1a clinical results for its anti-obesity drug candidate, GUBamy. The company advanced its transition from biotechnology to techbio, utilizing its proprietary streaMLine drug discovery platform and establishing a new TechBio lab. In sustainability, Gubra committed to the Science Based Targets initiative (SBTi) and progressed toward its goals of electric power self-sufficiency by 2025 and becoming carbon-negative and nature-positive by 2030. Additionally, the company maintained equal gender representation on its Board of Directors and other management teams.

Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.

Document Details

Report Year

2024

Reporting Period

Jan 1, 2024 - Dec 31, 2024

Fiscal Year

2024

Type

Annual Report with Sustainability Disclosures

Language

English

Pages

 

File Size

 

Standards & Assurance

Reporting Standards

Materiality Assessment

ESG Data?Experimental — AI-extracted data, may contain inaccuracies

Emissions

Scope 1:

Scope 2:

Scope 3:

Total Waste

Women on Board

Women in Management

Employees